Wedbush reissued their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note ...

Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price ...

Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.71% and 5.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Dianthus Therapeutics, a clinical-stage biotechnology company, has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology industry ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics ...